TY - JOUR T1 - What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2020-001339 VL - 6 IS - 2 SP - e001339 AU - Kristien Van der Elst AU - Elke G E Mathijssen AU - Ellen Landgren AU - Ann Bremander AU - An De Groef AU - Elisabet Lindqvist AU - Maria Nylander AU - Alma Peters AU - Frank Van den Hoogen AU - Yvonne van Eijk-Hustings AU - Gerard Verhoeven AU - Johanna E Vriezekolk AU - Rene Westhovens AU - Ingrid Larsson Y1 - 2020/09/01 UR - http://rmdopen.bmj.com/content/6/2/e001339.abstract N2 - Objectives To explore treatment outcomes preferred by patients with early rheumatoid arthritis (RA) and how these change throughout the early disease stage across three European countries.Methods A longitudinal, qualitative, multicentre study was conducted in Belgium, the Netherlands and Sweden. 80 patients with early RA were individually interviewed 3–9 months after treatment initiation and 51 of them participated again in either a focus group or an individual interview 12–21 months after treatment initiation. Data were first analysed by country, following the Qualitative Analysis Guide of Leuven (QUAGOL). Thereafter, a meta-synthesis, inspired by the principles of meta-ethnography and the QUAGOL, was performed, involving the local research teams.Results The meta-synthesis revealed 11 subthemes from which four main themes were identified: disease control, physical performance, self-accomplishment and well-being. ‘A normal life despite RA’ was an overarching patient-preferred outcome across countries. Belgian, Dutch and Swedish patients showed many similarities in terms of which outcomes they preferred throughout the early stage of RA. Some outcome preferences (eg, relief of fatigue and no side effects) developed differently over time across countries.Conclusions This study on patient-preferred outcomes in early RA revealed that patients essentially want to live a normal life despite RA. Our findings help to understand what really matters to patients and provide specific insights into the early stage of RA, which should be addressed by clinicians of different disciplines from the start of treatment onwards. ER -